Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas.

Kummar S, Gutierrez ME, Anderson LW, Klecker RW Jr, Chen A, Murgo AJ, Doroshow JH, Collins JM.

Cancer Chemother Pharmacol. 2013 Oct;72(4):917-23. doi: 10.1007/s00280-013-2244-4. Epub 2013 Aug 3.

PMID:
23912694
2.

Biodistribution and radiation dosimetry estimates of 1-(2'-deoxy-2'-(18)F-Fluoro-1-beta-D-arabinofuranosyl)-5-bromouracil: PET imaging studies in dogs.

Nimmagadda S, Mangner TJ, Sun H, Klecker RW Jr, Muzik O, Lawhorn-Crews JM, Douglas KA, Collins JM, Shields AF.

J Nucl Med. 2005 Nov;46(11):1916-22.

3.

Zebularine metabolism by aldehyde oxidase in hepatic cytosol from humans, monkeys, dogs, rats, and mice: influence of sex and inhibitors.

Klecker RW, Cysyk RL, Collins JM.

Bioorg Med Chem. 2006 Jan 1;14(1):62-6. Epub 2005 Sep 6.

PMID:
16143537
4.

Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactions.

Anderson LW, Collins JM, Klecker RW, Katki AG, Parchment RE, Boinpally RR, LoRusso PM, Ivy SP.

Cancer Chemother Pharmacol. 2005 Oct;56(4):351-7. Epub 2005 May 13.

PMID:
15895233
5.

Metabolism by N-acetyltransferase 1 in vitro and in healthy volunteers: a prototype for targeted inhibition.

Cantilena LR, Katki AG, Klecker RW, Collins JM.

J Clin Pharmacol. 2004 Dec;44(12):1405-11.

PMID:
15545312
6.

Distribution of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil in mice bearing colorectal cancer xenografts: rationale for therapeutic use and as a positron emission tomography probe for thymidylate synthase.

Eiseman JL, Brown-Proctor C, Kinahan PE, Collins JM, Anderson LW, Joseph E, Hamburger DR, Pan SS, Mathis CA, Egorin MJ, Klecker RW.

Clin Cancer Res. 2004 Oct 1;10(19):6669-76.

8.

Evaluation of highly bound drugs: interspecies, intersubject, and related comparisons.

Collins JM, Klecker RW Jr.

J Clin Pharmacol. 2002 Sep;42(9):971-5.

PMID:
12211222
9.

Thymidine phosphorylase as a target for imaging and therapy with thymine analogs.

Klecker RW Jr, Collins JM.

Cancer Chemother Pharmacol. 2001 Nov;48(5):407-12.

PMID:
11761459
10.
12.

Predicting drug interactions in vivo from experiments in vitro. Human studies with paclitaxel and ketoconazole.

Jamis-Dow CA, Pearl ML, Watkins PB, Blake DS, Klecker RW, Collins JM.

Am J Clin Oncol. 1997 Dec;20(6):592-9.

PMID:
9391548
13.

Rifampin and rifabutin and their metabolism by human liver esterases.

Jamis-Dow CA, Katki AG, Collins JM, Klecker RW.

Xenobiotica. 1997 Oct;27(10):1015-24.

PMID:
9364739
14.

Stereoselective metabolism of fenoldopam and its metabolites in human liver microsomes, cytosol, and slices.

Klecker RW, Collins JM.

J Cardiovasc Pharmacol. 1997 Jul;30(1):69-74.

PMID:
9268223
16.

Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy.

Wilson WH, Jamis-Dow C, Bryant G, Balis FM, Klecker RW, Bates SE, Chabner BA, Steinberg SM, Kohler DR, Wittes RE.

J Clin Oncol. 1995 Aug;13(8):1985-94.

PMID:
7636539
17.

Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences.

Jamis-Dow CA, Klecker RW, Katki AG, Collins JM.

Cancer Chemother Pharmacol. 1995;36(2):107-14.

PMID:
7767945
19.

Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography.

Takimoto CH, Klecker RW, Dahut WL, Yee LK, Strong JM, Allegra CJ, Grem JL.

J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):97-104.

PMID:
8061838
20.

Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion, and metabolism of [3H]taxol in the Sprague-Dawley rat.

Klecker RW, Jamis-Dow CA, Egorin MJ, Erkmen K, Parker RJ, Stevens R, Collins JM.

Drug Metab Dispos. 1994 Mar-Apr;22(2):254-8.

PMID:
7912177
21.

Effect of the mutation of tyrosine 713 in p93c-fes on its catalytic activity and ability to promote myeloid differentiation in K562 cells.

Fang F, Ahmad S, Lei J, Klecker RW, Trepel JB, Smithgall TE, Glazer RI.

Biochemistry. 1993 Jul 13;32(27):6995-7001.

PMID:
8334128
23.
24.

Dextran sulfate is poorly absorbed after oral administration.

Lorentsen KJ, Hendrix CW, Collins JM, Kornhauser DM, Petty BG, Klecker RW, Flexner C, Eckel RH, Lietman PS.

Ann Intern Med. 1989 Oct 1;111(7):561-6.

PMID:
2476054
25.

Iododeoxyuridine (IdUrd) incorporation into DNA of human hematopoietic cells, normal liver and hepatic metastases in man: as a radiosensitizer and as a marker for cell kinetic studies.

Speth PA, Kinsella TJ, Chang AE, Klecker RW Jr, Belanger K, Smith R, Rowland J, Cupp JE, Collins JM.

Int J Radiat Oncol Biol Phys. 1989 May;16(5):1247-50.

PMID:
2715075
26.

Selective incorporation of iododeoxyuridine into DNA of hepatic metastases versus normal human liver.

Speth PA, Kinsella TJ, Chang AE, Klecker RW, Belanger K, Collins JM.

Clin Pharmacol Ther. 1988 Oct;44(4):369-75.

27.

Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders.

Klecker RW Jr, Collins JM, Yarchoan RC, Thomas R, McAtee N, Broder S, Myers CE.

J Clin Pharmacol. 1988 Sep;28(9):837-42.

PMID:
2852679
28.

Fluorodeoxyuridine modulation of the incorporation of iododeoxyuridine into DNA of granulocytes: a phase I and clinical pharmacological study.

Speth PA, Kinsella TJ, Belanger K, Klecker RW Jr, Smith R, Rowland JB, Collins JM.

Cancer Res. 1988 May 15;48(10):2933-7.

29.

Pyrimidine dideoxyribonucleosides: selectivity of penetration into cerebrospinal fluid.

Collins JM, Klecker RW Jr, Kelley JA, Roth JS, McCully CL, Balis FM, Poplack DG.

J Pharmacol Exp Ther. 1988 May;245(2):466-70.

PMID:
3367302
30.

Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

Yarchoan R, Perno CF, Thomas RV, Klecker RW, Allain JP, Wills RJ, McAtee N, Fischl MA, Dubinsky R, McNeely MC, et al.

Lancet. 1988 Jan 16;1(8577):76-81.

PMID:
2891981
31.

Long-term administration of 3'-azido-2',3'-dideoxythymidine to patients with AIDS-related neurological disease.

Yarchoan R, Thomas RV, Grafman J, Wichman A, Dalakas M, McAtee N, Berg G, Fischl M, Perno CF, Klecker RW, et al.

Ann Neurol. 1988;23 Suppl:S82-7.

PMID:
2831806
33.

Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.

Ozols RF, Cunnion RE, Klecker RW Jr, Hamilton TC, Ostchega Y, Parrillo JE, Young RC.

J Clin Oncol. 1987 Apr;5(4):641-7.

PMID:
3559654
34.
35.

Incorporation of iododeoxyuridine into DNA of granulocytes in patients.

Belanger K, Klecker RW Jr, Rowland J, Kinsella TJ, Collins JM.

Cancer Res. 1986 Dec;46(12 Pt 1):6509-12.

36.

Selenium-induced cytotoxicity of human leukemia cells: interaction with reduced glutathione.

Batist G, Katki AG, Klecker RW Jr, Myers CE.

Cancer Res. 1986 Nov;46(11):5482-5.

37.

Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.

Yarchoan R, Klecker RW, Weinhold KJ, Markham PD, Lyerly HK, Durack DT, Gelmann E, Lehrman SN, Blum RM, Barry DW, et al.

Lancet. 1986 Mar 15;1(8481):575-80.

PMID:
2869302
38.

Prolonged treatment schedules with intraperitoneal 5-fluorouracil diminish the local-regional nature of drug distribution.

Sugarbaker PH, Klecker RW, Gianola FJ, Speyer JL.

Am J Clin Oncol. 1986 Feb;9(1):1-7.

PMID:
3953487
39.

Adriamycin accumulation and metabolism in adriamycin-sensitive and -resistant human ovarian cancer cell lines.

Louie KG, Hamilton TC, Winker MA, Behrens BC, Tsuruo T, Klecker RW Jr, McKoy WM, Grotzinger KR, Myers CE, Young RC, et al.

Biochem Pharmacol. 1986 Feb 1;35(3):467-72.

PMID:
3947382
40.

Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection.

Collins JM, Klecker RW Jr, Yarchoan R, Lane HC, Fauci AS, Redfield RR, Broder S, Myers CE.

J Clin Pharmacol. 1986 Jan;26(1):22-6.

PMID:
3005375
41.

Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo.

Broder S, Yarchoan R, Collins JM, Lane HC, Markham PD, Klecker RW, Redfield RR, Mitsuya H, Hoth DF, Gelmann E, et al.

Lancet. 1985 Sep 21;2(8456):627-30.

PMID:
2863631
42.

Clinical pharmacology of 5-iodo-2'-deoxyuridine and 5-iodouracil and endogenous pyrimidine modulation.

Klecker RW Jr, Jenkins JF, Kinsella TJ, Fine RL, Strong JM, Collins JM.

Clin Pharmacol Ther. 1985 Jul;38(1):45-51.

PMID:
4006375
43.

Phase I and pharmacokinetic study of tiazofurin (TCAR, NSC 286193) administered by continuous infusion.

Batist G, Klecker RW Jr, Jayaram HN, Jenkins JF, Grygiel J, Ihde DC, Eddy JL, Fine RL, Kerr IG, Collins JM.

Invest New Drugs. 1985;3(4):349-55.

PMID:
4086242
44.

Reversal of adriamycin resistance by verapamil in human ovarian cancer.

Rogan AM, Hamilton TC, Young RC, Klecker RW Jr, Ozols RF.

Science. 1984 Jun 1;224(4652):994-6.

PMID:
6372095
45.

Quantification of tiazofurin in plasma by high-performance liquid chromatography.

Klecker RW Jr, Collins JM.

J Chromatogr. 1984 May 11;307(2):361-9.

PMID:
6736183
46.

Pharmacological evaluation of intravenous delivery of 5-bromodeoxyuridine to patients with brain tumors.

Russo A, Gianni L, Kinsella TJ, Klecker RW Jr, Jenkins J, Rowland J, Glatstein E, Mitchell JB, Collins J, Myers C.

Cancer Res. 1984 Apr;44(4):1702-5.

47.

Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans.

Speyer JL, Sugarbaker PH, Collins JM, Dedrick RL, Klecker RW Jr, Myers CE.

Cancer Res. 1981 May;41(5):1916-22.

Supplemental Content

Loading ...
Support Center